RxDoctor Payments Data

Kim Davies, MD

Internal Medicine · Independence, MONPI 1326188046

Payments from drug & device makers

$2,810in general payments, 2019–2025

Across 79 payments — averaging $35.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$418
  • Eisai Inc.$338
  • Teva Pharmaceuticals USA, Inc.$316
  • Merck$246
  • Amgen$209
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$2,810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,810 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$13,243
Medicare patients
20
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$26,936
Xtampza ErOxycodone Myristate49$26,544
RybelsusSemaglutide16$22,706
BelsomraSuvorexant13$9,256
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen194$6,384
Chlorpromazine Hcl13$5,868
Oxycodone Hcl169$3,940
Gabapentin76$2,561
Lubiprostone11$1,944
Morphine Sulfate ErMorphine Sulfate87$1,840
Quetiapine Fumarate40$1,840
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen48$1,434
Oxcarbazepine28$1,430
Potassium Chloride48$1,307
Albuterol Sulfate HfaAlbuterol Sulfate55$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$418$49,64233 claims
Collegium Pharmaceutical, Inc.Xtampza Er$47$26,54449 claims
MerckBelsomra$246$9,25613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →